<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e>-<z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha activity has been correlated to <z:hpo ids='HP_0010972'>ineffective erythropoiesis</z:hpo> in lower risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Infliximab (Remicade(Â®)) is an anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha chimeric antibody that is used in the treatment of patients with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> or <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Forty-six patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and a relatively low risk of developing <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> were included in a randomized phase II study assessing the therapeutic activity of two dosages of infliximab administration (3 mg/kg vs. 5 mg/kg) </plain></SENT>
<SENT sid="3" pm="."><plain>The primary end point was the response rate </plain></SENT>
<SENT sid="4" pm="."><plain>Responses were observed in 3 of 22 patients (13.1%) randomized to the 3 mg/kg arm, versus 0 of 21 patients randomized in the 5 mg/kg arm </plain></SENT>
<SENT sid="5" pm="."><plain>According to the statistical design of the current study, neither of the two infliximab dose schedules tested showed sufficient activity as a single agent in this cohort of unselected patients with early <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
</text></document>